What Eyexora does

Eyexora is a global ophthalmology company that develops eye care therapies and medical devices using a hub-and-spoke operating model. Founded in 2025 and headquartered at 31 Hudson Yards in New York, with a co-headquarters established in Singapore, the company centralizes R&D, clinical, regulatory, and commercial expertise in a single operational hub that supports multiple wholly-owned subsidiary "spoke" companies. Each spoke houses a distinct therapeutic or device program, and the architecture is explicitly designed to balance de-risked, clinic-ready assets against higher-risk moonshots, reducing the time, cost, and probability of failure typical of single-asset ophthalmology pipelines.

The current portfolio consists of two wholly-owned spoke companies. Serenora Therapeutics is developing sub-conjunctivally delivered liposomal tacrolimus for chronic ocular surface inflammatory diseases, combining targeted sustained delivery with a validated immunomodulatory mechanism. Y.ora Vision is developing next-generation ophthalmic medical devices for glaucoma, extending the platform into the device modality. The company states intent to expand across retina, anterior segment diseases, and cell therapy through additional exclusive in-licensing and academic collaborations, with initial assets sourced from the Singapore Eye Research Institute (SERI). The leadership team combines 100+ years of collective ophthalmology experience, a track record of founding and exiting over 30 vision-care companies and products, and prior capital raises exceeding $1B across member ventures; seed financing was led by ClavystBio, a Temasek-established life sciences investor.

Eyexora is pre-commercial and has no marketed products or disclosed revenue. Its stated revenue model is pharmaceutical and therapeutic licensing and royalties, with eventual commercialization expected through standard pharmaceutical and medical device distribution channels following regulatory approval. Near-term counterparties are academic and clinical research partners (SERI and clinician-scientists) rather than paying customers, with the ultimate end market being patients suffering from vision-threatening ophthalmic diseases.

Name

Eyexora

Legal name

Eyexora Global, Inc.

Website

https://eyexora.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Eyexora is a pre-commercial ophthalmology company using a hub-and-spoke model to advance multiple eye care therapies and medical devices in parallel through wholly-owned subsidiaries. It targets patients with vision-threatening diseases, initially via assets in-licensed from the Singapore Eye Research Institute.

Ownership category

akta.pro rank

Product category

Ophthalmology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic therapeutics
• Eye care devices
• Ocular surface treatments
• Retinal disease therapies
• Glaucoma medical devices

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical and Therapeutic Licensing: Revenue anticipated from development and commercialization of ophthalmic therapeutics through subsidiary companies, leveraging hub expertise to advance programs through clinical development to market.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Eyexora develops ophthalmic therapeutics and medical devices through a hub-and-spoke model that centralizes R&D, clinical, regulatory, and commercial expertise across subsidiary "spoke" companies. Its initial pipeline includes sub-conjunctivally delivered liposomal tacrolimus for ocular surface inflammatory diseases (via Serenora Therapeutics) and next-generation ophthalmic medical devices for glaucoma (via Y.ora Vision). The company in-licenses foundational assets from the Singapore Eye Research Institute and balances de-risked clinic-ready programs with high-impact moonshots.

Product overview

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model that centralizes R&D, clinical, regulatory, and commercial expertise into one operational engine. The company advances multiple therapies and devices in parallel through focused subsidiaries. The core portfolio consists of two spoke companies: Serenora Therapeutics, Inc. (developing liposomal tacrolimus for ocular surface diseases) and Y.ora Vision, Inc. (developing next-generation glaucoma medical devices). The model balances de-risked, clinic-ready programs with high-impact moonshots across retina, anterior segment diseases, and cell therapy.

Differentiator

Problem solved

Functional benefit

Brands

• Serenora Therapeutics: First spoke company focused on accelerating development of sub-conjunctivally delivered liposomal tacrolimus for ocular surface inflammatory diseases.
• Y.ora Vision

Products and services

• Serenora Therapeutics, Inc. (sub-conjunctival liposomal tacrolimus program) Eyexora's first wholly-owned spoke company developing a sub-conjunctivally delivered liposomal formulation of tacrolimus that combines targeted sustained delivery with a validated immunomodulatory mechanism, intended as a safer, longer-lasting treatment for patients with chronic inflammation of the ocular surface.
• Y.ora Vision, Inc. (next-generation glaucoma medical device program) Eyexora's second wholly-owned spoke company developing next-generation ophthalmic medical devices for glaucoma, representing the company's expansion from therapeutics into device innovation.

Quantifiable outcome

• Founded, advised, built, capitalized, and exited over 30 companies and products in vision care and ophthalmology markets

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Y.ora Vision, Inc.coreOthers · 1 October 2025Eyexora's second spoke company, focused on developing next-generation ophthalmic medical devices for glaucoma. Created following licensing agreement between SERI and Eyexora Global. Complements initial spoke company Serenora Therapeutics.
• Singapore Eye Research Institute (SERI)coreStrategic or Co-development Partner · 10 September 2025Eyexora's initial assets were in-licensed from SERI, Singapore's national research institute for ophthalmic and vision research. SERI ranks first globally in eye publications per capita and has over 5,900 scientific papers and 188 patents. Collaboration reflects SERI's commitment to translating cutting-edge science into clinical solutions.
• Serenora Therapeutics, Inc.coreOthers · 1 August 2025Eyexora's first spoke company, created to accelerate development of sub-conjunctivally delivered liposomal tacrolimus for ocular surface inflammatory diseases. Combines targeted sustained delivery with validated immunomodulatory mechanism to offer safer, longer-lasting treatment options.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Kodiak Sciences: Clinical-stage biopharmaceutical company developing novel therapeutics for retinal diseases, with a pipeline of ABC platform-based molecules. Comparable to Eyexora in pursuing innovative ophthalmic therapeutics targeting chronic retinal conditions requiring long-duration dosing.
• Tarsus Pharmaceuticals: Ophthalmology-focused biotech built around a multi-asset platform approach (lead asset XDEMVY for Demodex blepharitis, plus pipeline expansion). Comparable to Eyexora as a focused, multi-asset ophthalmology company pursuing both commercial and development-stage opportunities in eye care.
• Adverum Biotechnologies: Clinical-stage gene-therapy company developing single-injection intravitreal treatments for wet AMD and diabetic macular edema. Comparable to Eyexora in targeting high-value retinal and ophthalmic indications with a differentiated, durable-treatment approach.
• Eyenovia: Ophthalmic drug-delivery platform developing microdose array-print technology for topical ocular therapeutics. Comparable to Eyexora in targeting differentiated ocular drug-delivery approaches to address adherence and efficacy limitations of standard eye drops.
• Ocuphire Pharma: Clinical-stage ophthalmology company developing both front- and back-of-eye therapies (Ryzumvi, Nyxol, APX3330). Comparable to Eyexora as a multi-asset ophthalmology biotech spanning multiple therapeutic areas and stages of development.
• Oculis: Clinical-stage ophthalmology biotech developing a multi-asset pipeline across retina, ocular surface, and neuro-ophthalmology. Comparable to Eyexora as a smaller, multi-program ophthalmology company pursuing both drugs and differentiated delivery approaches with global (US/Europe/Iceland) operations.
• REGENXBIO: Clinical-stage gene-therapy company with a leading ophthalmology program (ABBV-RGX-314, partnered with AbbVie, for wet AMD and diabetic retinopathy). Comparable to Eyexora as a multi-asset biotech with significant ophthalmology focus and platform-based innovation.
• EyePoint Pharmaceuticals: Specialty ophthalmology company focused on sustained-release ocular drug delivery, including FDA-approved DURYSTA for glaucoma. Directly comparable to Eyexora's Serenora spoke in targeting sustained-release delivery to the eye and to Y.ora Vision in addressing glaucoma.

Broad incumbents

• Bausch + Lomb: Global ophthalmology company with integrated businesses in vision care, ophthalmic pharmaceuticals, and surgical devices. Comparable to Eyexora as a broad incumbent competing across the same drug and device segments Eyexora's spoke companies are entering (notably glaucoma devices and ocular-surface therapeutics).
• Alcon: Global leader in eye care with a broad portfolio spanning surgical ophthalmology, vision care, and ophthalmic pharmaceuticals. Comparable to Eyexora as the dominant incumbent in the same addressable ophthalmology market Eyexora is targeting with both drug and device assets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eyexora

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyexora